慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2023.06.022

摘要/Abstract

摘要： 目的探讨慢性乙型肝炎(CHB)和乙型肝炎肝硬化患者外周血单个核细胞(PBMC)信号转导和转录激活因子3(STAT3)和血清可溶性CD30分子(sCD30)水平变化及其临床意义。方法 2019年12月～2021年12月我院诊治的CHB患者45例(HBeAg阳性25例,HBeAg阴性20例)和乙型肝炎肝硬化患者38例(代偿期22例,失代偿期16例),另选择健康人40例,分离PBMC,采用RT-PCR法检测STAT3 mRNA,采用ELISA法检测血清sCD30水平。给予两组患者抗病毒和护肝治疗。结果肝硬化组PBMC STAT3 mRNA和血清sCD30水平分别为(1.6±0.4)和(60.3±12.9)U/L,均显著高于CHB组【分别为(1.3±0.3)和(51.8±10.2)U/L,P＜0.05】或健康人【分别为(0.5±0.1)和(10.6±2.4)U/L,P＜0.05】;25例血清HBeAg阳性患者STAT3 mRNA和sCD30水平分别为(1.4±0.3)和(57.2±11.9)U/L,均显著高于20例HBeAg阴性患者【分别为(1.2±0.3)和(45.1±8.1),P＜0.05】,16例失代偿期肝硬化患者STAT3 mRNA和sCD30水平分别为(1.8±0.5)和(70.5±14.3)U/L,均显著高于22例代偿期肝硬化患者【分别为(1.4±0.3)和(52.9±11.8),P＜0.05】;经抗病毒或/和护肝治疗3个月和6个月,CHB患者STAT3 mRNA和sCD30水平呈进行性降低,其中肝硬化患者STAT3 mRNA和sCD30水平分别为(1.2±0.2)和(43.6±8.3)U/L及(0.7±0.2)和(21.5±3.7)U/L,显著低于治疗前(P＜0.05)。结论 CHB和乙型肝炎肝硬化患者PBMC STAT3和血清sCD30水平升高,与病情进展关系密切,值得临床进行监测和深入研究。

关键词: 肝硬化, 慢性乙型肝炎, 信号转导和转录激活因子3, 可溶性CD30, 临床意义

Abstract: Objective The purpose of this study was to investigate the implication of peripheral blood mononuclear cell (PBMCs) signal transducer and activator of transcription 3 (STAT3) and serum soluble CD30 (sCD30) levels in patients with chronic hepatitis B (CHB) and hepatitis B cirrhosis. Methods 45 patients with CHB and 38 patients with hepatitis B cirrhosis were encountered in our hospital between December 2019 and December 2021, and 40 healthy volunteers matched by gender and age were selected as control. The PBMCs were separated and the STAT3 mRNA was assayed by RT-PCR. Serum SCD30 level was detected by ELISA. All patients with CHB and hepatitis B cirrhosis received antiviral therapy, and the cirrhotics were also managed by liver-protecting medicines. Results The PBMC STAT3 mRNA load and serum sCD30 level in patients with liver cirrhosis were (1.6±0.4) and (60.3±12.9)U/L, both significantly higher than [(1.3±0.3) and (51.8±10.2)U/L, P＜0.05] in patients with CHB or [(0.5±0.1) and (10.6±2.4)U/L, respectively, P＜0.05] in healthy volunteers; the STAT3 mRNA and sCD30 level in 25 CHB patients with serum HBeAg positive were (1.4±0.3) and (57.2±11.9)U/L, both significantly higher than [(1.2±0.3) and (45.1±8.1), respectively P＜0.05] in 20 CHB patients with serum HBeAg negative, and the STAT3 mRNA and sCD30 level in 16 patients with decompensated cirrhosis were (1.8±0.5) and (70.5±14.3)U/L, both significantly higher than [(1.4±0.3) and (52.9±11.8), respectively, P＜0.05] in 22 patients with compensated cirrhosis; at the end of three-month and six-month treatment, the STAT3 mRNA and sCD30 level in patients with CHB and with hepatitis B cirrhosis decreased gradually, out of which, the STAT3 mRNA and sCD30 levels in patients with cirrhosis were (1.2±0.2) and (43.6±8.3)U/L, and (0.7±0.2) and (21.5±3.7)U/L, all significantly lower than at inclusion (P＜0.05). Conclusion The PBMC STAT3 and serum sCD30 levels in patients with CHB and hepatitis B cirrhosis are up-regulated, which might be related to the deterioration of the disease, and needs further investigation.

Key words: Liver Cirrhosis, Hepatitis B, Signal transducer and activator of transcription 3, Soluble CD30, Clinical implication

邹涛, 张敏, 杨凡, 王丽, 喻峰. 慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 855-858.

Zou Tao, Zhang Min, Yang Fan, et al. Implication of peripheral blood mononuclear cell signal transducer and activator of transcription 3 and serum soluble CD30 levels in patients with chronic hepatitis B and hepatitis B cirrhosis[J]. Journal of Practical Hepatology, 2023, 26(6): 855-858.

参考文献

[1] Kanda T, Goto T, Hirotsu Y, et al. Molecular mechanismsdriving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis B and C infections: a review. Int J Mol Sci,2019,20(6):1358-1360.
[2] Bharadwaj U, Kasembeli MM, Robinson P, et al. Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol Rev,2020,72(2):486-526.
[3] Cui ZY, Wang G, Zhang J, et al. Parthenolide, bioactive compound ofchrysanthemum parthenium L, ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway. Phytother Res,2021,35(10): 5680-5693.
[4] Park YJ, Jeon MS, Lee S, et al. Anti-fibrotic effects of brevilin A in hepatic fibrosis via inhibiting the STAT3 signaling pathway. Bioorg Med Chem Lett,2021,1(41):1279-1289.
[5] Li HG, You PT, Xia Y, et al. Yuganlong ameliorates hepatic fibrosis by inhibiting PI3K/AKT, Ras/ERK and JAK1/STAT3 signaling pathways in ccl4-induced liver fibrosis rats. Curr Med Sci,2020,40(3):539-547.
[6] Bharat A, Narayanan K, Golocheikine A, et al. Elevated soluble CD30 characterizes patients with hepatitis C virus-induced liver allograft cirrhosis. Transplantation,2017,84(12): 1704-1707.
[7] 王贵强,王福生,成军,等.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016, 19(3):389-400.
[8] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-786.
[9] Jia C, Wang G, Wang T, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition via thetransglutaminase 2-dependent IL-6/IL6R/STAT3 axis in hepatocellular carcinoma. Int J Biol Sci,2020,16(14):2542-2558.
[10] Li TY, Yang Y, Zhou G, et al. Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol,2019,25(27):3527-3537.
[11] Mohammed S, Nicklas EH, Thadathil N, et al. Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress. Free Radic Biol Med,2021,20(164):315-328.
[12] Zhao J, Qi YF, Yu YR. STAT3: A key regulator in liver fibrosis. Ann Hepatol,2021,5(21): 1002-1024.
[13] Li H, Liu NN, Li JR, et al. Bicyclol ameliorates advanced liver diseases in murine models via inhibiting the IL-6/STAT3 signaling pathway. Biomed Pharmacother,2022,6(150): 1130-1038.
[14] Martí A, Alegre F, Moragrega ÁB, et al. Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells. Gut,2020,69(5):920-932.
[15] Liang J, Yuan H, Xu L, et al. Study on the effect of Mongolian medicine Qiwei Qingganpowder on hepatic fibrosis through JAK2/STAT3 pathway. Biosci Biotechnol Biochem,2021,85(4):775-785.
[16] Lu ZN, Shan Q, Hu SJ, et al. Discovery of 1,8-naphthalidine derivatives as potent anti-hepatic fibrosis agents via repressing PI3K/AKT/Smad and JAK2/STAT3 pathways. Bioorg Med Chem,2021,1(49):11643-11648.
[17] Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feed forward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut,2018,67(9):1704-1715.
[18] Tang M, Chen Y, Li B, et al. Therapeutic targeting of STAT3 with small interference RNAs and antisense oligonucleotides embedded exosomes in liver fibrosis. FASEB J,2021, 35(5):2155-2157.
[19] Terzieva V, Mihova A, Altankova I, et al. The dynamic changes in soluble CD30 and regulatory T cells before and after solid organ transplantations: a pilot study. Monoclon Antib Immunodiagn Immunother,2019,38(4):137-144.
[20] Prator CA, Thanh C, Kumar S, et al. Circulating CD30⁺CD4⁺ T cells increase before human immunodeficiency virus rebound after analytical antiretroviral treatment interruption. J Infect Dis,2020,221(7):1146-1155.

慢性乙型肝炎和乙型肝炎肝硬化患者PBMCs 信号转导和转录激活因子3及血清可溶性CD30分子水平变化及其临床意义探讨^*

Implication of peripheral blood mononuclear cell signal transducer and activator of transcription 3 and serum soluble CD30 levels in patients with chronic hepatitis B and hepatitis B cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[2]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[3]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[4]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.
[5]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[6]	刘欢, 陈鹏, 蒯文涛, 徐亮. 肝脏硬度测定、血小板计数/脾厚比值和脾静脉直径预测肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 867-870.
[7]	贺梅年, 赵思佳, 田智超, 何秀英, 巴正武. 超声半定量评分结合弹性成像诊断慢性乙型肝炎患者早期肝硬化临床价值分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 871-874.
[8]	杨帆, 张小娟, 李丹, 姜莎莎, 张亮, 唐伟, 赵微. 胃镜下硬化术联合组织胶注射术治疗乙型肝炎肝硬化并发食管胃静脉曲张破裂出血患者1年再出血危险因素分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 875-878.
[9]	周莉, 丁云清, 袁凤英, 陈竹, 冯志伟. 超声造影判断乙型肝炎肝硬化患者肝内占位性病变性质价值研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 903-906.
[10]	刘明, 王金婷, 杨士彦, 杨位轩, 万元春. ESPBD与EST治疗肝硬化合并胆总管结石患者疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(6): 915-918.
[11]	盛秋菊, 窦晓光. 慢性HBV感染不同疾病状态治疗策略选择与获益评价[J]. 实用肝脏病杂志, 2023, 26(5): 609-611.
[12]	张丹, 丁洋. 慢性乙型肝炎患者病毒载量与疾病状态和治疗策略选择^*[J]. 实用肝脏病杂志, 2023, 26(5): 612-614.
[13]	吴育龙, 庄见齐, 刘志成, 马侠槟. 核苷(酸)类似物治疗慢性乙型肝炎患者血清HBV pgRNA变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 622-625.
[14]	王一卓, 张崴琪, 李红. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者3年随访研究[J]. 实用肝脏病杂志, 2023, 26(5): 626-629.
[15]	郝岸华, 杜忠彩, 周林, 马磊. 慢性乙型肝炎患者肝脏硬度检测和S指数变化及评估肝纤维化程度应用价值探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 630-633.